- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Zepdon ( Isentress )
Zepdon (raltegravir, also known by the brand name Isentress) is an antiretroviral medication belonging to the integrase strand transfer inhibitor (INSTI) class. It is indicated, in combination with other antiretroviral drugs, for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection in adults and children weighing at least 2 kg. Raltegravir blocks the HIV integrase enzyme, preventing the insertion of viral DNA into the host genome and thereby halting viral replication. It does not cure HIV, but when used as part of a complete suppressive regimen, it reduces the viral load to undetectable levels and preserves immune function.
Usual adult dose: The standard dose is 400 mg taken orally twice daily, with or without food. In patients who are virologically suppressed on a twice‑daily raltegravir regimen, a once‑daily regimen of 1200 mg (two 600 mg tablets) may be considered under the guidance of a healthcare professional, but the 400 mg twice‑daily schedule remains the typical starting dose. The tablets should be swallowed whole; they may be chewed or crushed if needed for administration via a nasogastric tube, as bioavailability is not altered. No dose adjustment is required in renal impairment; in hepatic impairment, no adjustment is needed for mild‑to‑moderate dysfunction, but use in severe hepatic impairment is not recommended. If a dose is missed, the patient should take it as soon as remembered; if it is within 4 hours of the next dose, the missed dose should be skipped. Two doses must never be taken at the same time. Raltegravir must always be used together with other antiretroviral agents; monotherapy is not appropriate.
Dosage form: Film‑coated tablets: 400 mg (pink, oval‑shaped, debossed with “227” on one side). Also available as 600 mg tablets, chewable tablets, and granules for oral suspension for paediatric use. The 400 mg tablet is the cornerstone of the twice‑daily regimen.
Onset of action: Antiviral activity is rapid; significant reductions in plasma HIV‑1 RNA are observed within the first 2 weeks of therapy when combined with an optimized background regimen. Undetectable viral loads (less than 50 copies/mL) are typically achieved within 16 to 24 weeks of continuous, adherent treatment.
Duration of action: Twice‑daily dosing maintains intracellular concentrations above the inhibitory threshold for the full 12‑hour interval. The elimination half‑life of raltegravir is approximately 9 hours, with a shorter terminal phase; virologic control is sustained only with strict adherence to the prescribed schedule.
Alcohol recommendation: No direct pharmacokinetic interaction between raltegravir and alcohol has been identified. However, excessive alcohol consumption may worsen hepatic function, especially in patients with co‑existing hepatitis B or C, and can impair adherence to antiretroviral therapy. Moderation is advisable, and patients with liver disease should consult their healthcare professional.
Most common side effects: Insomnia, headache, nausea, diarrhea, fatigue, and dizziness. Creatine kinase elevations and myalgia are occasionally reported. Serious adverse events include severe hypersensitivity reactions, including Stevens‑Johnson syndrome, which require immediate discontinuation. Hepatic transaminase elevations, sometimes accompanied by bilirubin increases, can occur; liver function should be monitored at baseline and periodically thereafter. As with all effective antiretroviral therapy, immune reconstitution inflammatory syndrome (IRIS) may develop, manifesting as an exaggerated inflammatory response to opportunistic infections. Raltegravir is not a cure for HIV; transmission of the virus to others through sexual contact or blood exposure remains possible despite a suppressed viral load. Patients must be counselled on the critical importance of adherence to avoid drug resistance. In Canada, raltegravir is available only by prescription and must be initiated by a healthcare professional experienced in HIV management.
Would you like to try Zepdon (raltegravir, also known by the brand name Isentress) without a prescription?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
